All In Biotech

Drug Trial Radar · NCT07327359

A Study to Evaluate Safety and Efficacy of OLX72021 in Healthy Males With Androgenetic Alopecia

A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Phase 1b/2a Study to Evaluate the Safety and Efficacy of OLX72021 in Healthy Males With Androgenetic Alopecia

Last checked: Nov 19, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 158 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

158

Planned (sponsor's estimate)

Start

Dec 4, 2025

Primary completion

Sep 2027

Study completion Sep 2027

Sponsor

Lead sponsor
Olix Pharmaceuticals, Inc.Industry
Sponsor type
Industry
Collaborators
Avance Clinical Pty Ltd.
First posted
Jan 8, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 18 years, up to 59 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study is designed to evaluate the safety, efficacy, tolerability, and pharmacokinetics (PK) of OLX72021 in medically healthy men with mild to moderate androgenetic alopecia.

Conditions

  • Androgenetic Alopecia (AGA)

Interventions

  • OLX72021Drug

    Low Dose

  • OLX72021Drug

    Mid Dose

  • OLX72021Drug

    High Dose

  • PlaceboDrug

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To investigate the incidence, type, severity, and relationship of adverse events (AEs)/serious AEs (SAEs), assessed using the CTCAE Version 5.0 (Phase 1b)Time frame: From baseline to end of study (Day 85)
  2. To assess local tolerability at intradermal (ID) injection site (Phase 1b)Time frame: From baseline to end of study (Day 85)
  3. To evaluate the change from baseline in non-vellus Target Area Hair Count (TAHC) at 24 weeks (Day 169) (Phase 2a)Time frame: Baseline to Day 169

Locations

8 sites in 2 countries. Site status is shown where the registry gives one.

  • Emeritus Research Sydney

    Botany, New South Wales, Australia · Not yet recruiting

  • St George Dermatology and Skin Cancer Centre

    Kogarah, New South Wales, Australia · Not yet recruiting

  • Genesis Research Services

    Newcastle, New South Wales, Australia · Not yet recruiting

  • Emeritus Research Camberwell

    Camberwell, Victoria, Australia · Recruiting

  • Sinclair Dermatology (t/a DIRECT)

    East Melbourne, Victoria, Australia · Not yet recruiting

  • Institute for Skin, Health and Immunity

    Mitcham, Victoria, Australia · Not yet recruiting

  • Optimal Clinical Trials Central

    Grafton, Auckland, New Zealand · Not yet recruiting

  • Optimal Clinical Trials North Shore

    North Shore, Auckland, New Zealand · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.